Laden…
Synapedia is an independent knowledge project about psychoactive substances and harm reduction. If the platform helps you learn something new, you can support its development.
Every bit helps keep the project alive.
5-amyl-2-[(1R,6R)-6-isopropenyl-3-methyl-cyclohex-2-en-1-yl]resorcinol
CBD (Cannabidiol) is a non-psychoactive cannabinoid from the cannabis plant, primarily known for its anti-inflammatory, anxiolytic, and neuroprotective properties. It mainly acts by modulating the endocannabinoid system and influences various receptors, including CB1, CB2, 5-HT1A, and TRPV1. Due to its favorable safety profile, CBD is increasingly being studied in research and medicine. It does not cause intoxicating effects and has a low risk of side effects or dependence.
Receptor Targets
Mechanism of Action
Designations
IUPAC: 5-amyl-2-[(1R,6R)-6-isopropenyl-3-methyl-cyclohex-2-en-1-yl]resorcinol
CBD interacts with the endocannabinoid system, particularly with the CB1 and CB2 receptors. It modulates the effects of endocannabinoids and has potentially anti-inflammatory and anxiolytic properties.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Total duration 4-8 hours
Peak
1-3 hours (oral), 30-90 minutes (sublingual), 30 minutes (vaporized)
Onset
30-90 minutes (oral), 15-30 minutes (sublingual), 5-10 minutes (vaporized)
Total duration
4-8 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, and pre-existing conditions significantly affect outcomes.
Risks & Harm Reduction is partially translated. Some content may appear in German.
Risks
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
CYP-Hemmung kann Benzodiazepin-Plasmaspiegel erhöhen
CBD ist ein klinisch relevanter CYP3A4-Inhibitor. Viele Benzodiazepine werden über CYP3A4 metabolisiert (Alprazolam, Midazolam, Triazolam, Diazepam teilweise). Die Hemmung kann zu erhöhten Benzodiazepinspiegeln und verstärkter Sedierung, Ataxie und Atemdepressionsrisiko führen. Lorazepam und Oxazepam werden über Glucuronidierung abgebaut und sind weniger betroffen.
CYP-Hemmung und milde Interaktion
CBD hemmt CYP3A4 und CYP2C19, die am Metabolismus einiger SSRI (z. B. Sertralin, Citalopram) beteiligt sind. Dies kann zu erhöhten SSRI-Plasmaspiegeln führen. Zusätzlich hat CBD eine 5-HT1A-agonistische Wirkung, die mit der serotonergen Aktivität der SSRI milde additiv wirken kann. In klinisch üblichen CBD-Dosen ist das Risiko gering, aber bei hochdosierter CBD-Anwendung sind pharmakokinetische Interaktionen möglich.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.